394 related articles for article (PubMed ID: 18166352)
1. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition.
Robinson A; Keely S; Karhausen J; Gerich ME; Furuta GT; Colgan SP
Gastroenterology; 2008 Jan; 134(1):145-55. PubMed ID: 18166352
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis.
Marks E; Goggins BJ; Cardona J; Cole S; Minahan K; Mateer S; Walker MM; Shalwitz R; Keely S
Inflamm Bowel Dis; 2015 Feb; 21(2):267-75. PubMed ID: 25545377
[TBL] [Abstract][Full Text] [Related]
3. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.
Karhausen J; Furuta GT; Tomaszewski JE; Johnson RS; Colgan SP; Haase VH
J Clin Invest; 2004 Oct; 114(8):1098-106. PubMed ID: 15489957
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological HIF-1 stabilization promotes intestinal epithelial healing through regulation of α-integrin expression and function.
Goggins BJ; Minahan K; Sherwin S; Soh WS; Pryor J; Bruce J; Liu G; Mathe A; Knight D; Horvat JC; Walker MM; Keely S
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G420-G438. PubMed ID: 33470153
[TBL] [Abstract][Full Text] [Related]
5. Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.
Keely S; Campbell EL; Baird AW; Hansbro PM; Shalwitz RA; Kotsakis A; McNamee EN; Eltzschig HK; Kominsky DJ; Colgan SP
Mucosal Immunol; 2014 Jan; 7(1):114-23. PubMed ID: 23695513
[TBL] [Abstract][Full Text] [Related]
6. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function.
Tambuwala MM; Cummins EP; Lenihan CR; Kiss J; Stauch M; Scholz CC; Fraisl P; Lasitschka F; Mollenhauer M; Saunders SP; Maxwell PH; Carmeliet P; Fallon PG; Schneider M; Taylor CT
Gastroenterology; 2010 Dec; 139(6):2093-101. PubMed ID: 20600011
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia and gastrointestinal disease.
Taylor CT; Colgan SP
J Mol Med (Berl); 2007 Dec; 85(12):1295-300. PubMed ID: 18026919
[TBL] [Abstract][Full Text] [Related]
8. Lipophilic modification enhances anti-colitic properties of rosmarinic acid by potentiating its HIF-prolyl hydroxylases inhibitory activity.
Jeong S; Park H; Hong S; Yum S; Kim W; Jung Y
Eur J Pharmacol; 2015 Jan; 747():114-22. PubMed ID: 25483211
[TBL] [Abstract][Full Text] [Related]
9. Oxygen sensing in intestinal mucosal inflammation.
Flück K; Fandrey J
Pflugers Arch; 2016 Jan; 468(1):77-84. PubMed ID: 26206140
[TBL] [Abstract][Full Text] [Related]
10. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.
Bernhardt WM; Câmpean V; Kany S; Jürgensen JS; Weidemann A; Warnecke C; Arend M; Klaus S; Günzler V; Amann K; Willam C; Wiesener MS; Eckardt KU
J Am Soc Nephrol; 2006 Jul; 17(7):1970-8. PubMed ID: 16762988
[TBL] [Abstract][Full Text] [Related]
11. Local Stabilization of Hypoxia-Inducible Factor-1α Controls Intestinal Inflammation
Kim YI; Yi EJ; Kim YD; Lee AR; Chung J; Ha HC; Cho JM; Kim SR; Ko HJ; Cheon JH; Hong YR; Chang SY
Front Immunol; 2020; 11():609689. PubMed ID: 33519819
[TBL] [Abstract][Full Text] [Related]
12. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.
Knowles HJ; Tian YM; Mole DR; Harris AL
Circ Res; 2004 Jul; 95(2):162-9. PubMed ID: 15192023
[TBL] [Abstract][Full Text] [Related]
13. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase.
Jeon H; Kim H; Choi D; Kim D; Park SY; Kim YJ; Kim YM; Jung Y
Mol Pharmacol; 2007 Jun; 71(6):1676-84. PubMed ID: 17377063
[TBL] [Abstract][Full Text] [Related]
14. Prolyl hydroxylase inhibitor treatment confers whole-animal hypoxia tolerance.
Kasiganesan H; Sridharan V; Wright G
Acta Physiol (Oxf); 2007 Jun; 190(2):163-9. PubMed ID: 17394573
[TBL] [Abstract][Full Text] [Related]
15. Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD.
Hindryckx P; De Vos M; Jacques P; Ferdinande L; Peeters H; Olievier K; Bogaert S; Brinkman B; Vandenabeele P; Elewaut D; Laukens D
J Immunol; 2010 Nov; 185(10):6306-16. PubMed ID: 20943999
[TBL] [Abstract][Full Text] [Related]
16. Short-term effects of pharmacologic HIF stabilization on vasoactive and cytotrophic factors in developing mouse brain.
Schneider C; Krischke G; Keller S; Walkinshaw G; Arend M; Rascher W; Gassmann M; Trollmann R
Brain Res; 2009 Jul; 1280():43-51. PubMed ID: 19450570
[TBL] [Abstract][Full Text] [Related]
17. Piceatannol, a hydroxystilbene natural product, stabilizes HIF-1α protein by inhibiting HIF prolyl hydroxylase.
Yum S; Doh HJ; Hong S; Jeong S; Kim DD; Park M; Jung Y
Eur J Pharmacol; 2013 Jan; 699(1-3):124-31. PubMed ID: 23261967
[TBL] [Abstract][Full Text] [Related]
18. HIF-prolyl hydroxylases and cardiovascular diseases.
Sen Banerjee S; Thirunavukkarasu M; Tipu Rishi M; Sanchez JA; Maulik N; Maulik G
Toxicol Mech Methods; 2012 Jun; 22(5):347-58. PubMed ID: 22424133
[TBL] [Abstract][Full Text] [Related]
19. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis.
Cummins EP; Seeballuck F; Keely SJ; Mangan NE; Callanan JJ; Fallon PG; Taylor CT
Gastroenterology; 2008 Jan; 134(1):156-65. PubMed ID: 18166353
[TBL] [Abstract][Full Text] [Related]
20. Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD.
Tanaka T; Nangaku M
J Pharmacol Sci; 2009 Jan; 109(1):24-31. PubMed ID: 19151537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
